How to see with your eyes closed
New York, NY–(BUSINESS WIRE)–Ophthalmology New York announced today that it has acquired eye-tracking software company EyeEm and acquired a company that helps doctors better understand the eye, in a deal that will be announced today.
EyeEm, which helps clinicians and patients make better diagnosis and treatment decisions, will be renamed EyeEm Medical and will operate independently of the company that provides the software and services.
EyeEM Medical will continue to provide eye tracking solutions and research to hospitals and doctors, and will remain independent of EyeEm.
“I’m thrilled to be part of a company which has built an incredible brand, a strong community and a solid business model that has helped shape the way we see the world,” said Dr. Joseph J. Filippo, president and CEO of EyeEM.
“This deal provides us with a platform that will enable us to provide our customers with the most relevant information and help them make better clinical decisions.
I look forward to continuing to work closely with our partners to deliver the best quality vision care for patients and their families.”
The acquisition is expected to close in the second quarter of 2017.
The acquisition is subject to customary closing conditions.
EyeEm has been developing eye tracking software that can be used to track eye movements and facial expressions.
Eye Em Medical has developed a suite of apps for doctors and patients to track their eye movements, and the software is designed to help doctors and clinicians make better diagnoses and treatment choices.
“I am incredibly proud to join with Dr. Fannin and the entire EyeEm team,” said Filippa.
“Their vision for eye tracking was so important to me as an ophthalmologist, and I’m excited to bring that vision to the world.
EyeEm will continue as a private company under a non-compete agreement that is subject at the time of the acquisition to a termination provision. “
We are excited to be working with them on future research and to continue to work with them to deliver new technologies and services that make our lives better,” said J. David Cohen, CEO of Ophthalmology and head of Eye Em.
EyeEm will continue as a private company under a non-compete agreement that is subject at the time of the acquisition to a termination provision.
The EyeEm acquisition was first reported by The Wall Street Journal.
In addition to Dr. J.
Fannin, the deal includes: Older Eye Medicine CEO and Founder, Dr. Brian O’Neill; Empirical and Vision Research Center CEO, Drs.
Jerald and Catherine Tischman; and CEO, Lisa Moll, the CEO of Dr. Scott Lohr, the Ophthalmologists Optometry and Head of the Center for Eye Imaging, and Dr. Anthony Schafer, the Director of the Eye and Ear Institute, both of which will remain in place.
As part of the transaction, EyeEm will also be acquired by Vision Research.
With this acquisition, Eye Em has expanded its vision into the OTC market.
Eyeem’s existing software and platform will continue, and Visionre will be used in conjunction with EyeEm’s software and product.
For more information about the EyeEm deal, please visit: www.eyeemmedical.com For additional information, contact Mark G. Hickey, CEO, at: [email protected]
SOURCE Eye Em Medicine Inc.